Stock SAKAR SAKAR HEALTHCARE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sakar Healthcare Limited

Equities

SAKAR

INE732S01012

Pharmaceuticals

Delayed NSE India S.E.
Other stock markets
 11:20:33 21/05/2024 am IST 		5-day change 1st Jan Change
347 INR +0.42% Intraday chart for Sakar Healthcare Limited -3.09% -13.25%
06/03 Sakar Healthcare Ltd Receives EU GMP Approval Dated 5th March 2024With A Validity of Three Years from Audited Date CI
10/02 Sakar Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 652.2 739.1 747.3 1,766 2,313 3,819
Enterprise Value (EV) 1 794 852.9 911.3 2,192 3,171 4,976
P/E ratio 23.3 x 10.5 x 7.77 x 16 x 15.2 x 29.2 x
Yield - - - - - -
Capitalization / Revenue 1.22 x 1.07 x 0.89 x 1.85 x 1.79 x 2.85 x
EV / Revenue 1.49 x 1.24 x 1.09 x 2.3 x 2.46 x 3.71 x
EV / EBITDA 6.14 x 4.87 x 4.41 x 9.45 x 10.7 x 14.6 x
EV / FCF -26.7 x -7.53 x 94.9 x -17.2 x -4.17 x -6.77 x
FCF Yield -3.74% -13.3% 1.05% -5.81% -24% -14.8%
Price to Book 1.41 x 1.03 x 0.92 x 1.79 x 1.82 x 2.2 x
Nbr of stocks (in thousands) 10,961 14,961 14,961 15,618 17,118 19,040
Reference price 2 59.50 49.40 49.95 113.1 135.2 200.6
Announcement Date 20/09/18 16/08/19 22/08/20 14/08/21 22/08/22 24/08/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 534.2 688.1 839.1 953.1 1,291 1,342
EBITDA 1 129.3 175 206.8 231.8 295 341
EBIT 1 85.21 114.6 136 151.3 205.6 191.2
Operating Margin 15.95% 16.65% 16.21% 15.87% 15.93% 14.25%
Earnings before Tax (EBT) 1 61.09 97.19 122.3 132.3 189.3 169.9
Net income 1 38.15 70.11 96.23 106.8 151.8 127.6
Net margin 7.14% 10.19% 11.47% 11.21% 11.76% 9.51%
EPS 2 2.550 4.686 6.432 7.086 8.902 6.862
Free Cash Flow 1 -29.73 -113.3 9.601 -127.4 -760.5 -735.2
FCF margin -5.57% -16.47% 1.14% -13.37% -58.9% -54.79%
FCF Conversion (EBITDA) - - 4.64% - - -
FCF Conversion (Net income) - - 9.98% - - -
Dividend per Share - - - - - -
Announcement Date 20/09/18 16/08/19 22/08/20 14/08/21 22/08/22 24/08/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 142 114 164 425 857 1,157
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.097 x 0.6508 x 0.7929 x 1.834 x 2.906 x 3.391 x
Free Cash Flow 1 -29.7 -113 9.6 -127 -760 -735
ROE (net income / shareholders' equity) 8.77% 11.4% 12.6% 11.9% 13.4% 8.48%
ROA (Net income/ Total Assets) 7.02% 7.97% 8% 6.46% 5.77% 3.96%
Assets 1 543.3 880.1 1,203 1,654 2,631 3,225
Book Value Per Share 2 42.20 47.90 54.40 63.00 74.50 91.00
Cash Flow per Share 2 0.3000 0.2500 0.2000 0.0500 0.0200 0.0500
Capex 1 88.1 249 133 355 975 822
Capex / Sales 16.49% 36.2% 15.86% 37.29% 75.54% 61.25%
Announcement Date 20/09/18 16/08/19 22/08/20 14/08/21 22/08/22 24/08/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
SAKAR HEALTHCARE LIMITED Stock Sakar Healthcare Limited
-13.25% 80.46M
MERCK KGAA Stock Merck KGaA
+15.58% 78.65B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+9.75% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-10.76% 5.16B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+54.31% 4.85B
YUHAN CORPORATION Stock Yuhan Corporation
+11.19% 4.19B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-22.37% 2.32B
INDIVIOR PLC Stock Indivior PLC
+12.49% 2.29B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-30.09% 2.19B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+20.63% 2.19B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SAKAR Stock
  4. Financials Sakar Healthcare Limited
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW